The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no ...
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
Recursion Pharmaceuticals, Inc. ( RXRX) announced Wednesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 trial of REC-4881 ...
Java4Shell (CVE-2026-114938) is a critical OpenJDK Base64 decoder bug that can lead to RCE. See who’s affected, how to check ...
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Doug ...
Recursion Pharmaceuticals said on November 18, 2026 that it had aligned with the U.S. Food and Drug Administration on a ...
RXRX is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.27 since the market last closed. This is a 9.93 ...
Transformer on MSNOpinion

Policy can still work on short timelines

Transformer Weekly: California makes a bid to regulate AI, a new FRONTIER ACT, and Anthropic’s record-breaking IPO ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Here’s an overview of some of last week’s most interesting news, articles, interviews and videos: Malware spread through ...